Clinical trial
A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)
NCT06033950 is registered in ClinicalTrials.gov with Colorado Prevention Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)
- Lead sponsor
- Colorado Prevention Center
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- August 20, 2024
- Completion date
- January 31, 2028
- Enrollment
- 2,600 (estimated)
- Sites
- 176
Conditions
As the registry lists them; a condition with its own page is linked.